Allurion (ALUR) files 12b-25 for late 10-Q; anticipates material change
Allurion Technologies, Inc. filed a Form 12b-25 notifying the SEC that its Form 10-Q for the quarter ended June 30, 2025 could not be filed on time.
Rhea-AI Filing Summary
Allurion Technologies, Inc. filed a Form 12b-25 notifying the SEC that its Form 10-Q for the quarter ended June 30, 2025 could not be filed on time. The notice identifies Brendan M. Gibbons, Chief Legal Officer as the contact and confirms that other periodic reports required over the prior 12 months have been filed. The company indicates it anticipates a significant change in results of operations for the period and includes customary forward-looking risk disclosures about potential adjustments to prior statements, regulatory or legal actions, possible delisting, and timing uncertainties related to completing and filing the 10-Q.
Positive
- Form 12b-25 was filed to formally notify the SEC of the delayed Form 10-Q
- All other periodic reports over the prior 12 months were reported as filed
- Company identified a named contact (Brendan M. Gibbons, Chief Legal Officer) for follow-up
Negative
- Form 10-Q for quarter ended June 30, 2025 was not filed on time, creating an information gap for investors
- Company anticipates a significant change in results of operations but provided no quantitative figures in this notice
- Filing discloses risks including possible restatements, regulatory investigations, lawsuits, delinquent filings, and potential NYSE delisting
Insights
TL;DR: The company timely notified the SEC of a delayed 10-Q and identified risks that could materially affect filings or listing status.
Allurion used Form 12b-25 to state it cannot file the Form 10-Q for the quarter ended June 30, 2025 within the prescribed time. The filing properly names a contact and confirms other required reports are current. The company explicitly flags a likely significant change in operating results and lists potential consequences including adjustments to prior financials, regulatory inquiries, possible delisting, and litigation risk. From a compliance standpoint, the notice is appropriate but raises governance and disclosure concerns until the 10-Q is filed.
TL;DR: Missing 10-Q creates short-term information gap; forward-looking risks increase uncertainty for investors.
The 12b-25 indicates the registrant expects material changes in results of operations but provides no quantitative detail in this notice. That absence leaves investors without the quarterly financial metrics needed to assess near-term performance. The explicit mention of potential restatements and evaluations of instruments (RIFA and convertible notes) suggests accounting issues under review. The impact is neutral-to-negative pending the actual 10-Q content, but materiality cannot be assessed until full financial disclosures are filed.
FAQ
Why did Allurion (ALUR) file Form 12b-25?
Has Allurion filed other required periodic reports in the past 12 months?
Who is the contact for questions about this filing?
Does the notice say whether results will change materially?
What risks does the Form 12b-25 identify?
AI-generated analysis. How Rhea-AI works. Not financial advice.